Invest in PlantForm
Investment opportunities are available as PlantForm brings its subsequent entry biologic (SEB) version of Herceptin to market. We've already demonstrated in the lab that our SEB trastuzumab has equivalent purity and activity; now we're preparing for a Phase 1 clinical trial in humans.
Herceptin can cost up to $100,000 per breast cancer patient per year, making access to more affordable treatments a priority for patients and health-care providers alike.
PlantForm's proprietary platform technology allows us to produce fully active, SEB versions of approved antibody drugs for as little as 10 per cent of the manufacturing cost of the name-brand alternatives.
We intend to launch our SEB trastuzumab, in partnership with a pharmaceutical company, in initial world markets in the 2015 to 2016 timeframe.
Help us make life-saving antibody medicine more affordable for people around the world.
For secure access to confidential PlantForm investment documents, please contact:
Don Stewart
President and CEO
don.stewart@plantformcorp.com
416.452.7242
Why Invest?
"PlantForm is ideally positioned to meet the fast-growing demand for affordable antibody medicines: it has a novel, versatile and scalable manufacturing platform with an excellent management team that can execute on a well thought-out plan."
Peter Pekos
PlantForm investor
President & CEO, Dalton Chemical Laboratories Inc.
An expert panel of Canadian and U.S. venture capitalists selected PlantForm as a leading investment opportunity and winner in the life sciences category of Canada's Top 10™ Competition (2010 and 2008/09).